 Blueprint Medicines Corporation NASDAQ: BPMC, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on August 1, 2020, the Compensation Committee of Blueprint Medicines Board of Directors granted non-qualified stock options to purchase an aggregate of 14,514 shares of its common stock and an aggregate of 7,255 restricted stock units RSUs to six new employees under Blueprint Medicines 2020 Inducement Plan. 